Remove 2020 Remove Immunization Remove Labelling
article thumbnail

EU gives narrower label to Apellis, Sobi’s PNH drug

pharmaphorum

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The post EU gives narrower label to Apellis, Sobi’s PNH drug appeared first on.

article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

The management of SLE and LN consists largely of treatment options that are based on highly efficacious steroids or immune-suppressive therapy with an undesirable safety profile, which includes accrued organ damage, infections and cancer. in 2018 across the 7MM despite being an off-label therapy for lupus.

Labelling 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Phase III trial shows tislelizumab improves outcomes for liver cancer patients

European Pharmaceutical Review

HCC accounted for more approximately 85 percent of the 900,000 new liver cancer cases in 2020, according to the Globocan 2020 database. . The RATIONALE 301 Phase III randomised, open-label study included more than 600 patients in the US, Europe and Asia. About tislelizumab.

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology.

Vaccines 134
article thumbnail

ASCO21: Gilead sets up first FDA okay for adult ALL with Tecartus data

pharmaphorum

Kymriah (tisagenlecleucel) was approved for relapsed/refractory ALL in 2017, but its label covers use in children and young adults aged up to 25, who account for the bulk of cases of the blood cancer. Around a quarter of patients treated with Tecartus had a severe immune reaction, and there were two deaths in the trial.

Labelling 105
article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

The vaccination of patients with AN1792 led to the activation of their immune systems, which started producing endogenous anti-Abeta antibodies. Therefore, active immunotherapy to trigger the immune system to produce sustained levels of endogenous antibodies has now become far more attractive.

article thumbnail

Positive safety data for long-term use of MS drug Kesimpta

pharmaphorum

The findings were based on an ALITHIOS Phase 3b open-label extension study of Kesimpta, a targeted B-cell therapy that Novartis says, “delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment for MS.”. years vs initiation two years later. billion in 2019.